XIAO ZHI HE GAN Capsules Combined With Polyene Phosphatidylcholine Capsule Clinical Observation Of Treatment Of Nonalcoholic Steatohepatitis

Objective:Xiaogan City, Hubei Province Chinese Medicine Hospital out-patient department in June2011-2012in June admitted through retrospective analysis of68cases of non-alcoholic fatty liver disease, cases of patients observed of Cellulite and liver capsule joint multi-polyene phosphatidylcholine capsulethe treatment of non-alcoholic steatohepatitis clinical outcomes.Methods:68patients with non-alcoholic steatohepatitis patients were randomly divided into2groups. Basic treatment:2groups of patients are given:(1) an appropriate control diet, control the intake of high-fat, high-energy food.(2) appropriate to strengthen the movement.(3)hypertension were treated with antihypertensive medication.(4)withtype2diabetes were treated with hypoglycemic medication.(5)2groups of patients observed disable lipid-lowering Hugan drugs two weeks before treatment. Experimental treatment:34patients of the control group polyene phosphatidylchol ine capsule,2/3times/day, orally. Treatment group,34patients on the basis of the oral polyene phosphatidylcholine capsule plus clothing of Cellulite and liver capsule,4/3times/day, orally. A month for a course, three courses of treatment. A month for a course, understand the patient’s clinical symptoms after three courses of treatment, serum lipids (TG), liver function (ALT, AST, GGT, etc.) as well as liver B ultrasound or CT scan. Statistically mean, measurement data using t test, counting a total efficiency of inspection, observation, comparison treatment group and the control group, the final ization of the polyene phosphatidylcholine Cellulite and liver capsule joint capsule the treatment of non-alcoholic steatohepatitis (NASH) clinical treatment effect.Results:3course of treatment,68patients with non-alcoholic steatohepatitis patients of liver function and triglyceride:treatment group AST, ALT, GGT than that before treatment have been greatly improved (P<0.05), TG treatmentthe former has decreased to some extent, but the decline was not statistically significant. Greater improvement (P<0.05) than before treatment control group, ALT, AST, GGT, TG than before treatment have reduced, but the change was not statistically significant (P<0.05).2efficacy change:after the end of treatment, the number of control treatment group of10people,14markedly effective number7, the invalid number3, the total effective rate was91.2%in the control group4, markedly the number9, the effective number11, invalid number of10people, with a total effective rate of61.6%, the difference between the two groups was significant(P<0.05), there were statistically significantConclusions:Cellulite and liver capsule has a good effect in the clinical treatment of non-alcohol ic steatohepatitis (NASH), has greatly improved from the test data as well as clinical symptoms in patients, deserves further observation.